Obsessive-compulsive disorder (OCD) is a severe and debilitating neuropsychiatric condition that has an estimated lifetime prevalence of 2.5–3.0% of the general population (1). Approximately 40% of patients treated for OCD do not respond to standard and second-line augmentation treatments (2). Treatment-refractory OCD tends to have a chronic and disabling course. Although psychological interventions, namely exposure and response prevention (ERP), have been shown to be effective in treating OCD and as an augmentation strategy for poor response to selective serotonin reuptake inhibitors (SSRIs) (3), many patients cannot engage in exposure therapy or do not respond to such treatments. Some patients with OCD also have adverse reactions to SSRIs and this makes alternative biological options for treating OCD more attractive. With increasing interest in biological therapies for OCD such as deep brain stimulation (DBS), it is important that advances in biological approaches to treating treatment resistant OCD are evaluated.

Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders / Pasquini, M; Brakoulias, V; Pallanti, S.. - In: FRONTIERS IN PSYCHIATRY. - ISSN 1664-0640. - 25 Febbraio(2020). [10.3389/fpsyt.2020.00093]

Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders.

Pasquini M
Primo
Writing – Review & Editing
;
2020

Abstract

Obsessive-compulsive disorder (OCD) is a severe and debilitating neuropsychiatric condition that has an estimated lifetime prevalence of 2.5–3.0% of the general population (1). Approximately 40% of patients treated for OCD do not respond to standard and second-line augmentation treatments (2). Treatment-refractory OCD tends to have a chronic and disabling course. Although psychological interventions, namely exposure and response prevention (ERP), have been shown to be effective in treating OCD and as an augmentation strategy for poor response to selective serotonin reuptake inhibitors (SSRIs) (3), many patients cannot engage in exposure therapy or do not respond to such treatments. Some patients with OCD also have adverse reactions to SSRIs and this makes alternative biological options for treating OCD more attractive. With increasing interest in biological therapies for OCD such as deep brain stimulation (DBS), it is important that advances in biological approaches to treating treatment resistant OCD are evaluated.
2020
glutamate; insight; neuromodulation; obsessive-compulsive disorder; refractoriness
01 Pubblicazione su rivista::01m Editorial/Introduzione in rivista
Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders / Pasquini, M; Brakoulias, V; Pallanti, S.. - In: FRONTIERS IN PSYCHIATRY. - ISSN 1664-0640. - 25 Febbraio(2020). [10.3389/fpsyt.2020.00093]
File allegati a questo prodotto
File Dimensione Formato  
Pasquini_Advances in Biological Approaches_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 191.34 kB
Formato Adobe PDF
191.34 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1387852
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact